News
--Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader- based medicines, today announced that Markus Warmuth, M.D., Chief Executive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback